Patient P-02014

Synthetic patientMETA-24 · Day 169 · 65–74 · M · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Unstable

Inflammatory state

Improving

Nutritional resilience

Unstable

Discontinuation risk

73%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 71 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 79 GI-04 recommended — GI Support Protocol GI-04
Day 80 Patient accepted — Started GI-04 in the companion
Day 88 GI symptom burden −23% vs expected — GI Support Protocol GI-04
Day 94 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 71.

Primary contributors, last 14 days

Inflammatory activity-23
GI instability-13
Toxicity-11
Nutritional resilience+3

What helped?

GI Support Protocol GI-04Day 79
Result: symptom burden −23%

LIFE OS recommendation

Monitoring Escalation ME-01

89%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 48
- WearableHRV 19 ms, trending down
Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 62 and rising
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑45
- WearableResting HR 75 bpm
- Wearable3,092 steps/day
Drug metabolism and exposure ↑20
- BloodToxicity index 43

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 3 · butyrate capacity 46/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 18 ms
Sleep: 6.9 h
Steps: 1,522
Resting HR: 74 bpm

Daily log: GI score 62, nutritional resilience 33, adherence 45.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02574	56%	S14	ME-01	improved	45
P-02505	52%	S14	NP-02	improved	45
P-02628	52%	S14	SC-12	improved	47
P-02057	51%	S14	GI-04	improved	47
P-02633	51%	S14	NP-02	improved	48
P-02035	49%	S19	GI-04	improved	53
P-02132	48%	S14	SC-12	improved	40
P-02320	48%	S14	NP-02	improved	50
P-02348	48%	S14	GI-04	improved	49
P-02118	47%	S14	GI-04	improved	47
P-02542	47%	S14	NP-02	improved	44
P-02648	46%	S14	SC-12	improved	47